Lowering apolipoprotein CIII delays onset of type 1 diabetes
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Serum levels of apolipoprotein CIII (apoCIII) are increased in type 1 diabetic patients, and when β cells are exposed to these diabetic sera, apoptosis occurs, an effect abolished by an antibody against apoCIII. We have investigated the BB rat, an animal model that develops a human-like type 1 diabetes, and found that apoCIII was also increased in sera from prediabetic rats. This increase in apoCIII promoted β-cell death. The endogenous levels of apoCIII were reduced by treating prediabetic animals with an antisense against this apolipoprotein, resulting in a significantly delayed onset of diabetes. ApoCIII thus serves as a diabetogenic factor, and intervention with this apolipoprotein in the prediabetic state can arrest disease progression. These findings suggest apoCIII as a target for the treatment of type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“On the contrary, about 5% of the Lancaster (PA) Amish population are heterozygous carriers of a null mutation (R19X) in the gene encoding apoCIII, and this results in a lifelong 50% reduction of the apoCIII levels and an apparent cardioprotection (13).”
Background
Cited by
The use of animal models in diabetes research
King, A. J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01911.x · Cited by 1,303
Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
“Finally, apoC-III levels are increased in type 1 diabetic patients and are also thought to be a cofactor in pancreatic β cell death.(4,35) Taken together, these results support the concept that apoC-III is a multifunctional protein that not only regulates the metabolism of triglyceride-rich lipoproteins, but may also…”
BackgroundSelf-citationExperimental Diabetes Mellitus in Different Animal Models
Al-awar, A., Kupai, K., Veszelka, M., Szűcs, G., Attieh, Z., Murlasits, Z., Török, S., Pósa, A., & Varga, C. (2016) · Journal of Diabetes Research · doi:10.1155/2016/9051426 · Cited by 305
Experimental animal models for diabetes and its related complications—a review
Kottaisamy, C. P. D., Raj, D. S., Prasanth Kumar, V., & Sankaran, U. (2021) · Laboratory Animal Research · doi:10.1186/s42826-021-00101-4 · Cited by 263
Apolipoprotein C-III: from pathophysiology to pharmacology
Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182
“Furthermore, apoC-III contributes to b cell disruption [78]; therefore, lowering apoC-III levels delays the onset of type 1 diabetes mellitus [79].”
Background
Metadata
- Authors
- Holmberg, R., Refai, E., Höög, A., Crooke, R. M., Graham, M., Olivecrona, G., Berggren, P.-O., & Juntti-Berggren, L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-06-13
- Volume
- 108
- Issue
- 26
- Pages
- 10685-10689
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1965740352
- Cited by
- 59
- References
- 1
- FWCI
- 3.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lowering apolipoprotein CIII delays onset of type 1 diabetes. https://app.cochat.ai/papers/10.1073/pnas.1019553108
- The paper
- Holmberg, R., Refai, E., Höög, A., Crooke, R. M., Graham, M., Olivecrona, G., Berggren, P.-O., & Juntti-Berggren, L. (2011). Lowering apolipoprotein CIII delays onset of type 1 diabetes. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1019553108
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.